Biologic response to anti-CD16 monoclonal antibody therapy in a human immuno- deficiency virus-related immune thrombocytopenic purpura patient. Blood 1993; 81:15-9.Soubrane C, Tourani JM, Andrieu JM, Visonneau S, Beldjord K, Israel-Biet D, Mouawad R, Bussel J, Weil M, Khayat D: ...
Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy. J Control Release. 2022 Jan 19;343:78-88. doi: 10.1016/j.jconrel.2022.01.021. Epub ahead of print. PMID: 35065158. » View on PubMed ...
candidate therapeutics and worth of further evaluation in animal models and potentially in humans for therapy of HIV-1 infections with the final goal of its eradication. Results Design and initial characterization of anti-HIV-1 BiKEs We have previously identified antibody domains (Ads), D6 and E1...
Induction therapy is usually effecti... A Federico,DRW Jayne - 《Nephrol Dial Transplant》 被引量: 68发表: 2014年 Pig kidney graft survival in a baboon for 136days: longest life‐supporting organ graft survival to date p>The longest survival of a non-human primate with a life-supporting ...
In addition, NK cell function is often suppressed or absent in patients with myeloma, as a result of the tumor itself or from its therapy, further reducing the effectiveness of daratumumab. Collectively, preclinical and clinical observations suggest a potential therapeutic benefit of maintaining NK ...
Anti-CD20 Ab therapy has proven successful for treating B cell malignancies and a number of autoimmune diseases. However, how anti-CD20 Abs operate in vivo... F Montalvao,Z Garcia,S Celli,... - 《Journal of Clinical Investigation》 被引量: 200发表: 2013年 Antibody-mediated B-cell depleti...
V. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011, 7, 349–359. [2]. Nimmerjahn, F.; Ravetch, J. V. Anti-inflammatory actions of intravenous immunoglobulin. Ann. Rev. Immunol. 2008, 26, 513–533. [3]. Bruhns, P.; Samuelsson, A.; Pollard, J. ...
monoclonal antibody (MAb) was previously shown to induce remission of Hodgkin’s disease refractory to chemo- and radiotherapy through specific activation of natural killer (NK) cells, but the appearance of a human anti-mouse antibody (HAMA) response prevented its use for prolonged therapy. Here...
PT-CD16VS is an allogeneic cell therapy derived from human postpartum placental circulating T (P-T) cells that are genetically modified to express a proprietary CD16 variant and endogenous T cell receptor (TCR) knockout. Here we report the characterization and preclinical evaluation of PT-CD16...
Taken together, our findings induced this hope that cord blood stem cell derived CD16+NK cells exploit antitumor immune response in cancer therapy with using anti-CD47 antibody.doi:10.1016/j.lfs.2019.117223Behnaz ValipourAli AbedelahiElahe Naderali...